Statins and the potential for higher diabetes mellitus risk

References

• Yandrapalli S, Gupta S, Andries G, et al. Drug therapy of dyslipidemia in the elderly. Drugs Aging. 2019;36(4):321–340.
   PubMed Web of Science ®Google Scholar
• Yandrapalli S, Nabors C, Goyal A, et al. Modifiable risk factors in young adults with first myocardial infarction. J Am Coll Cardiol. 2019;73(5):573–584.
   PubMed Web of Science ®Google Scholar
• Rochlani Y, Kattoor AJ, Pothineni NV, et al. Balancing Primary Prevention and Statin-Induced Diabetes Mellitus Prevention. Am J Cardiol. 2017;120(7):1122–1128.
   PubMed Web of Science ®Google Scholar
• Ward Natalie C, Watts Gerald F, Eckel Robert H. Statin toxicity. Circ Res. 2019;124(2):328–350.
   PubMed Web of Science ®Google Scholar
• Ahmadizar F, Ochoa-Rosales C, Glisic M, et al. Associations of statin use with glycaemic traits and incident type 2 diabetes. Br J Clin Pharmacol. 2019;85(5):993–1002.
   PubMed Web of Science ®Google Scholar
• Yandrapalli S, Jolly G, Horblitt A, et al. Cardiovascular benefits and safety of non-insulin medications used in the treatment of type 2 diabetes mellitus. Postgrad Med. 2017;129(8):811–821.
   PubMed Web of Science ®Google Scholar
• Freeman Dilys J, John N, Naveed S, et al. Pravastatin and the development of diabetes mellitus. Circulation. 2001;103(3):357–362.
   PubMed Web of Science ®Google Scholar
• Cederberg H, Stančáková A, Yaluri N, et al. Increased risk of diabetes with statin treatment is associated with impaired insulin sensitivity and insulin secretion: a 6 year follow-up study of the METSIM cohort. Diabetologia. 2015;58(5):1109–1117.
   PubMed Web of Science ®Google Scholar
• PM R, Pradhan A, MacFadyen JG, et al. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet Lond Engl. 2012;380(9841):565–571.
   PubMed Web of Science ®Google Scholar
• Rajpathak SN, Kumbhani DJ, Crandall J, et al. Statin therapy and risk of developing type 2 diabetes: a meta-analysis. Diabetes Care. 2009;32(10):1924–1929.
   PubMed Web of Science ®Google Scholar
• Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet Lond Engl. 2010;375(9716):735–742.
   PubMed Web of Science ®Google Scholar
• Mills EJ, Wu P, Chong G, et al. Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170 255 patients from 76 randomized trials. QJM Int J Med. 2011;104(2):109–124.
   PubMed Web of Science ®Google Scholar
• Culver AL, Ockene IS, Balasubramanian R, et al. Statin use and risk of diabetes mellitus in postmenopausal women in the women’s health initiative. Arch Intern Med. 2012;172(2):144–152.
   PubMed Web of Science ®Google Scholar
• Waters DD, Ho JE, DeMicco DA, et al. Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials. J Am Coll Cardiol. 2011;57(14):1535–1545.
   PubMed Web of Science ®Google Scholar
• Preiss D, Seshasai SRK, Welsh P, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA. 2011;305(24):2556–2564.
   PubMed Web of Science ®Google Scholar
• Navarese EP, Buffon A, Andreotti F, et al. Meta-analysis of impact of different types and doses of statins on new-onset diabetes mellitus. Am J Cardiol. 2013;111(8):1123–1130.
   PubMed Web of Science ®Google Scholar
• Carter AA, Gomes T, Camacho X, et al. Risk of incident diabetes among patients treated with statins: population based study. BMJ. 2013;346:f2610.
   PubMed Web of Science ®Google Scholar
• Zaharan NL, Williams D, Bennett K. Statins and risk of treated incident diabetes in a primary care population. Br J Clin Pharmacol. 2013;75(4):1118–1124.
   PubMed Web of Science ®Google Scholar
• Simsek S, Schalkwijk CG, Wolffenbuttel BHR. Effects of rosuvastatin and atorvastatin on glycaemic control in type 2 diabetes—the CORALL study. Diabet Med. 2012;29(5):628–631.
   PubMed Web of Science ®Google Scholar
• Teramoto T. Pitavastatin: clinical effects from the LIVES Study. Atheroscler Suppl. 2011;12(3):285–288.
   PubMed Web of Science ®Google Scholar
• Sukhija R, Prayaga S, Marashdeh M, et al. Effect of statins on fasting plasma glucose in diabetic and nondiabetic patients. J Investig Med. 2009;57(3):495–499.
   PubMed Web of Science ®Google Scholar
• Khan Safi U, Hammad R, Victor O, et al. Association of lowering low‐density lipoprotein cholesterol with contemporary lipid‐lowering therapies and risk of diabetes mellitus: a systematic review and meta‐analysis. J Am Heart Assoc. 2019;8(7):e011581.
   PubMedGoogle Scholar
• Lee S-E, Sung JM, Cho I-J, et al. Risk of new-onset diabetes among patients treated with statins according to hypertension and gender: results from a nationwide health-screening cohort. PloS One. 2018;13(4):e0195459.
   PubMed Web of Science ®Google Scholar
• Zigmont VA, Shoben AB, Lu B, et al. Statin users have an elevated risk of dysglycemia and new-onset-diabetes. Diabetes Metab Res Rev. 2019 May;e3189. DOI:10.1002/dmrr.3189
   PubMedGoogle Scholar
• Crandall JP, Mather K, Rajpathak SN, et al. Statin use and risk of developing diabetes: results from the diabetes prevention program. BMJ Open Diabetes Res Care. 2017;5(1):e000438.
   PubMed Web of Science ®Google Scholar
• Corrao G, Ibrahim B, Nicotra F, et al. Statins and the risk of diabetes: evidence from a large population-based cohort study. Diabetes Care. 2014;37(8):2225–2232.
   PubMed Web of Science ®Google Scholar
• Jung KM, Jeong JA, Jung KY, et al. Time‐ and dose‐dependent association of statin use with risk of clinically relevant new‐onset diabetes mellitus in primary prevention: a nationwide observational cohort study. J Am Heart Assoc. 2019;8(8):e011320.
   PubMedGoogle Scholar
• Aiman U, Najmi A, Khan RA. Statin induced diabetes and its clinical implications. J Pharmacol Pharmacother. 2014;5(3):181–185.
   PubMedGoogle Scholar
• Cui JY, Zhou RR, Han S, et al. Statin therapy on glycemic control in type 2 diabetic patients: a network meta-analysis. J Clin Pharm Ther. 2018;43(4):556–570.
   PubMed Web of Science ®Google Scholar
• Salunkhe VA, Elvstam O, Eliasson L, et al. Rosuvastatin treatment affects both basal and glucose-induced insulin secretion in INS-1 832/13 Cells. PloS One. 2016;11(3):e0151592.
   PubMed Web of Science ®Google Scholar
• Mabuchi H, Higashikata T, Kawashiri M, et al. Reduction of serum ubiquinol-10 and ubiquinone-10 levels by atorvastatin in hypercholesterolemic patients. J Atheroscler Thromb. 2005;12(2):111–119.
   PubMed Web of Science ®Google Scholar
• Donath MY, Böni-Schnetzler M, Ellingsgaard H, et al. Islet inflammation impairs the pancreatic beta-cell in type 2 diabetes. Physiol Bethesda Md. 2009;24:325–331.
   PubMed Web of Science ®Google Scholar
• Besseling J, Kastelein JJP, Defesche JC, et al. Association between familial hypercholesterolemia and prevalence of type 2 diabetes mellitus. JAMA. 2015;313(10):1029–1036.
   PubMed Web of Science ®Google Scholar
• Supale S, Li N, Brun T, et al. Mitochondrial dysfunction in pancreatic β cells. Trends Endocrinol Metab TEM. 2012;23(9):477–487.
   PubMed Web of Science ®Google Scholar
• Wang C-H, Wang -C-C, Huang H-C, et al. Mitochondrial dysfunction leads to impairment of insulin sensitivity and adiponectin secretion in adipocytes. Febs J. 2013;280(4):1039–1050.
   PubMed Web of Science ®Google Scholar
• Phielix E, Mensink M. Type 2 diabetes mellitus and skeletal muscle metabolic function. Physiol Behav. 2008;94(2):252–258.
   PubMed Web of Science ®Google Scholar
• Sirvent P, Fabre O, Bordenave S, et al. Muscle mitochondrial metabolism and calcium signaling impairment in patients treated with statins. Toxicol Appl Pharmacol. 2012;259(2):263–268.
   PubMed Web of Science ®Google Scholar
• Nakata M, Nagasaka S, Kusaka I, et al. Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control. Diabetologia. 2006;49(8):1881–1892.
   PubMed Web of Science ®Google Scholar
• Swerdlow DI, Preiss D, Kuchenbaecker KB, et al. HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. Lancet Lond Engl. 2015;385(9965):351–361.
   PubMed Web of Science ®Google Scholar
• Lotta LA, Sharp SJ, Burgess S, et al. Association between low-density lipoprotein cholesterol-lowering genetic variants and risk of type 2 diabetes: a meta-analysis. JAMA. 2016;316(13):1383–1391.
   PubMed Web of Science ®Google Scholar
• Sugiyama T, Tsugawa Y, Tseng C-H, et al. Different time trends of caloric and fat intake between statin users and nonusers among US adults: gluttony in the time of statins? JAMA Intern Med. 2014;174(7):1038–1045.
   PubMed Web of Science ®Google Scholar
• Jula A, Marniemi J, Huupponen R, et al. Effects of diet and simvastatin on serum lipids, insulin, and antioxidants in hypercholesterolemic men: a randomized controlled trial. JAMA. 2002;287(5):598–605.
   PubMed Web of Science ®Google Scholar
• Srikanthan P, Hevener AL, Karlamangla AS. Sarcopenia exacerbates obesity-associated insulin resistance and dysglycemia: findings from the National Health and Nutrition Examination Survey III. PloS One. 2010;5(5):e10805.
   PubMed Web of Science ®Google Scholar
• Wang K-L, Liu C-J, Chao T-F, et al. Statins, risk of diabetes, and implications on outcomes in the general population. J Am Coll Cardiol. 2012;60(14):1231–1238.
   PubMed Web of Science ®Google Scholar
• Taylor F, Huffman MD, Macedo AF, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2013;1:CD004816. DOI:10.1002/14651858.CD004816.pub5.
   PubMed Web of Science ®Google Scholar
• Zagelbaum NK, Yandrapalli S, Nabors C, et al. Bempedoic acid (ETC- 1002):ATP citrate lyase inhibitor: review of a first-in-class medication with potential benefit in statin-refractory cases. Cardiol Rev. 2019 Jan–Feb;27(1):49–56.
   PubMed Web of Science ®Google Scholar